Metformina Cinfa

Metformin Hydrochloride, the active ingredient in Metformina Cinfa, is a biguanide presented as an oral tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes and related glucose‑handling disorders.

GNH USA supplies Metformina Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina Cinfa, a biguanide antidiabetic, acts on glucose metabolism to lower elevated blood sugar levels.

- Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c. - Prediabetes (impaired fasting glucose): delays progression to overt diabetes. - Gestational diabetes (when diet alone is insufficient): helps maintain maternal glucose within target ranges.

Metformina Cinfa may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, especially during treatment initiation. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Loss of appetite: reduced desire to eat. - Flatulence: increased gas production.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hypoglycemia: when combined with insulin or sulfonylureas. - Vitamin B12 deficiency: long‑term use may reduce B12 absorption.

Before initiating Metformina Cinfa, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters.

- Renal function: assess creatinine clearance and avoid use in severe renal impairment. - Hepatic function: evaluate liver enzymes; contraindicated in acute liver disease. - Risk of lactic acidosis: avoid in conditions predisposing to hypoxia or severe infection. - Concomitant medications: review drugs that may affect renal clearance or increase acidosis risk. - Gastrointestinal tolerance: advise patients to take with meals to reduce upset. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformina Cinfa can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and lactic acidosis. - Cimetidine: can increase metformin plasma concentrations. - Alcohol: potentiates risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics: can affect renal function and metformin clearance. - ACE inhibitors/ARBs: monitor renal function and electrolytes. - NSAIDs: may reduce renal perfusion, increasing metformin levels. - Sulfonylureas: heightened risk of hypoglycemia when combined.